Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program.

Variational AI, developer of the Enki™ generative artificial intelligence (AI) drug discovery platform to redefine the economics of drug development, today announced that the company has filed two provisional patents with the United States Patent and Trademark Office

Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leader Jennifer Hamilton, Ph.D. as a company advisor.

Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leaders Dr. John F. Boylan and Dr. Mads Daugaard to the company’s Scientific Advisory Board.

Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecule therapeutics, today announced that it has added industry leaders Alexander Tropsha, Ph.D. and Robert N. Young, Ph.D. to the company’s Scientific Advisory Board.